Real-World Efficacy and Safety of Adalimumab Biosimilar (HS016) in Biologic-Naïve Patients with Perianal Fistulizing Crohn’s Disease: A Prospective, Single-Arm, Observational Study

HS016 exhibits significant efficacy and an acceptable safety profile in biologic-naïve PFCD patients, though the incremental maintenance strategy shows limited efficacy.